CN109641968B - Tim-4拮抗剂和pd-1拮抗剂的组合及其使用方法 - Google Patents

Tim-4拮抗剂和pd-1拮抗剂的组合及其使用方法 Download PDF

Info

Publication number
CN109641968B
CN109641968B CN201780054101.9A CN201780054101A CN109641968B CN 109641968 B CN109641968 B CN 109641968B CN 201780054101 A CN201780054101 A CN 201780054101A CN 109641968 B CN109641968 B CN 109641968B
Authority
CN
China
Prior art keywords
seq
tim
cancer
antibody
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780054101.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN109641968A (zh
Inventor
S·多伊尔
M·J·塞尔比
E·查德威克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN109641968A publication Critical patent/CN109641968A/zh
Application granted granted Critical
Publication of CN109641968B publication Critical patent/CN109641968B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201780054101.9A 2016-07-06 2017-07-05 Tim-4拮抗剂和pd-1拮抗剂的组合及其使用方法 Active CN109641968B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359073P 2016-07-06 2016-07-06
US62/359,073 2016-07-06
PCT/US2017/040665 WO2018009507A1 (en) 2016-07-06 2017-07-05 Combination of tim-4 antagonist and methods of use

Publications (2)

Publication Number Publication Date
CN109641968A CN109641968A (zh) 2019-04-16
CN109641968B true CN109641968B (zh) 2023-10-20

Family

ID=59366515

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780054101.9A Active CN109641968B (zh) 2016-07-06 2017-07-05 Tim-4拮抗剂和pd-1拮抗剂的组合及其使用方法

Country Status (7)

Country Link
US (2) US11306143B2 (enExample)
EP (1) EP3481866B1 (enExample)
JP (1) JP7164512B2 (enExample)
KR (1) KR102602137B1 (enExample)
CN (1) CN109641968B (enExample)
ES (1) ES2992868T3 (enExample)
WO (1) WO2018009507A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101411165B1 (ko) * 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
WO2018009507A1 (en) 2016-07-06 2018-01-11 Bristol-Myers Squibb Company Combination of tim-4 antagonist and methods of use
US20220363776A1 (en) * 2019-10-04 2022-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
CN110982824B (zh) * 2019-10-09 2022-04-15 天津大学 拮抗pd-1的抗体类似物bp基因及蛋白和应用
US11774451B2 (en) * 2019-11-21 2023-10-03 The Board Of Trustees Of The Leland Stanford Junior University Molecular vibrational spectroscopic markers for detection of cancer
WO2022165511A1 (en) * 2021-01-29 2022-08-04 Lapix Therapeutics, Inc. Tartaric acid analogs and uses thereof
EP4384552A4 (en) * 2021-08-10 2025-07-09 Heat Biologics Inc GENERATION AND CHARACTERIZATION OF NOVEL TIM-4 BINDING AGENTS
CN117940407A (zh) 2021-08-13 2024-04-26 Lapix生物治疗股份有限公司 降低免疫不耐受和治疗自身免疫病症的组合物和方法
CN115957304A (zh) * 2022-10-18 2023-04-14 山东大学 Tim-4调控胆固醇合成中的应用
AU2024207355A1 (en) * 2023-01-13 2025-08-21 Chimagen Biosciences, Ltd Multi-specific polypeptide complexes
WO2025077833A1 (en) * 2023-10-11 2025-04-17 Suzhou Neologics Bioscience Co., Ltd. Antibodies targeting tim-3 and pd-1 and uses thereof
CN117904122B (zh) * 2023-12-22 2025-01-28 北京贝来药业有限公司 一种编码抗pd-1抗体的基因及其修饰干细胞的制备和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101035561A (zh) * 2004-03-24 2007-09-12 特罗斯药品公司 作为改善对疫苗的免疫反应的佐剂的组合物和使用方法
CN102861319A (zh) * 2004-03-12 2013-01-09 布赖汉姆妇女医院 通过调节tim-1、tim-2和tim-4功能从而调节免疫应答的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
AU643109B2 (en) 1990-12-14 1993-11-04 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
AU3382595A (en) 1994-07-29 1996-03-04 Smithkline Beecham Corporation Novel compounds
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
EP3757130A1 (en) * 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JP2015209376A (ja) * 2014-04-24 2015-11-24 国立大学法人北海道大学 腫瘍特異的免疫増強剤
WO2018009507A1 (en) 2016-07-06 2018-01-11 Bristol-Myers Squibb Company Combination of tim-4 antagonist and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102861319A (zh) * 2004-03-12 2013-01-09 布赖汉姆妇女医院 通过调节tim-1、tim-2和tim-4功能从而调节免疫应答的方法
CN101035561A (zh) * 2004-03-24 2007-09-12 特罗斯药品公司 作为改善对疫苗的免疫反应的佐剂的组合物和使用方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints;Koyama S等;《Nature Communications》;20160229;10501 *
Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas;Kim J E等;《Clinical Cancer Research》;20160629;第23卷(第5期);124-136 *
Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas;Baghdadi M等;《Cancer Immunology Immunotherapy》;20121110;第64卷(第4期);629-637 *
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity;Sakuishi K等;《Journal of Experimental Medicine》;20100927;第207卷(第10期);2187-2194 *

Also Published As

Publication number Publication date
JP2019524701A (ja) 2019-09-05
KR102602137B1 (ko) 2023-11-13
US20190389950A1 (en) 2019-12-26
CN109641968A (zh) 2019-04-16
WO2018009507A8 (en) 2019-02-07
ES2992868T3 (en) 2024-12-19
KR20190026843A (ko) 2019-03-13
EP3481866A1 (en) 2019-05-15
US11306143B2 (en) 2022-04-19
US20220275091A1 (en) 2022-09-01
US12227575B2 (en) 2025-02-18
WO2018009507A1 (en) 2018-01-11
EP3481866B1 (en) 2024-07-24
JP7164512B2 (ja) 2022-11-01

Similar Documents

Publication Publication Date Title
CN109641968B (zh) Tim-4拮抗剂和pd-1拮抗剂的组合及其使用方法
US20220098302A1 (en) Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
CN108368178B (zh) 抗lag3抗体及其用途
CN113166268B (zh) 双特异性抗muc16 x抗cd28抗体以及其用途
CN113164598B (zh) 双特异性抗cd28 x抗cd22抗体以及其用途
JP5864266B2 (ja) 可溶型のｃｔｌａ−４に特異的に対する抗体
KR102130865B1 (ko) 암을 치료하기 위한 항-kir 항체와 항-pd-1 항체의 조합물
AU2018219909B2 (en) Radiolabeled anti-LAG3 antibodies for immuno-PET imaging
CN113754768A (zh) 结合cd39的抗体及其用途
KR20180133493A (ko) 인간 cd40에 결합하는 효능성 항체 및 이의 용도
KR20150061041A (ko) 인간 ｏｘ４０ 수용체에 대한 결합 분자
US20180246113A1 (en) Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
JP2024164199A (ja) Ｐｓｍａおよびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用
KR20220066346A (ko) 항-il-27 항체 및 이의 용도
KR20230135637A (ko) 새로운 활성을 갖는 hhla2 결합제

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment